Search products, brands, articles, and pages
Federal regulatory status, the authoritative source for state-by-state legislative tracking, and kratom.com's analysis of legislation we work alongside. Maintained for journalists, staffers, and researchers covering kratom policy.
FDA
Targeted action on 7-OH
On 29 July 2025, in a joint FDA / HHS announcement, the FDA formally recommended that 7-hydroxymitragynine (7-OH) — concentrated and synthetic 7-OH products specifically — be placed in Schedule I of the Controlled Substances Act. This is a targeted recommendation, narrower than the broad 2016 attempt to schedule kratom as a whole, and is consistent with the FDA's earlier "Hiding in Plain Sight" public-health communication distinguishing natural-leaf kratom from concentrated 7-OH material.
DEA
Active rulemaking on 7-OH
Following the FDA's July 2025 recommendation, the DEA is in an active rulemaking process specifically on concentrated and synthetic 7-OH products. As of early 2026, kratom whole leaf continues to be listed as a Drug of Concern rather than a controlled substance; the rulemaking targets the 7-OH category, not the plant.
HHS
Recommendation finalised
The earlier "review pending" posture was replaced by the joint 29 July 2025 announcement, in which HHS — alongside FDA — formally recommended Schedule I placement for concentrated and synthetic 7-OH. The next step now sits with the DEA rulemaking process.
Authoritative source
The American Kratom Association maintains the authoritative state-by-state legislative tracker for kratom — bills filed, status changes, KCPA adoption, federal action. For current state-by-state status, refer to their tracker.
The analysis cards below are interpretive briefs — a reading of legislation written for industry, researchers, and reporters rather than a status feed.
Visit americankratom.orgA consumer-facing visual reference is also available on the state-by-state guide — same dataset rendered as an interactive map, written for consumer rather than research depth.
Kratom.com Editorial · Regulatory Affairs
Comparative legislative analysis · 2024 edition
A reading of the AKA-maintained KCPA model and the state-by-state variations that matter for businesses operating in the category — particularly the 7-hydroxymitragynine cap variants and the registration regimes that change market-by-market planning.
U.S. Food and Drug Administration · Public Health Focus
The FDA's consolidated public-health communication on concentrated and synthetic 7-hydroxymitragynine products — drawing the regulatory line between whole-leaf kratom and 7-OH-concentrated material. The position kratom.com aligns with on product scope.
School of Pharmacy, Concordia University Wisconsin
Institutional white paper · December 2022
An independent application of the FDA's eight-factor scheduling framework to kratom by the Concordia University Wisconsin School of Pharmacy. Concludes that the available evidence does not support Schedule I classification — a parallel finding to Henningfield et al.'s 2022 update, prepared by an independent academic team.
Welcome
kratom.com is intended for adults 21 years of age or older. Confirm your age to continue.
By continuing you agree to our terms and age verification policy.